Logos Global Management as of June 30, 2021
Portfolio Holdings for Logos Global Management
Logos Global Management holds 57 positions in its portfolio as reported in the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Alx Oncology Hldgs (ALXO) | 14.5 | $173M | 3.2M | 54.68 | |
| Olema Pharmaceuticals (OLMA) | 8.8 | $105M | 3.7M | 27.98 | |
| Design Therapeutics (DSGN) | 4.6 | $54M | 2.7M | 19.89 | |
| Verve Therapeutics (VERV) | 3.8 | $46M | 758k | 60.25 | |
| Dyne Therapeutics (DYN) | 3.6 | $43M | 2.1M | 21.04 | |
| Deciphera Pharmaceuticals (DCPH) | 3.4 | $40M | 1.1M | 36.61 | |
| Karuna Therapeutics Ord | 3.1 | $37M | 325k | 113.99 | |
| Graphite Bio | 2.8 | $33M | 1.1M | 30.73 | |
| Instil Bio | 2.8 | $33M | 1.7M | 19.32 | |
| Compass Pathways Sponsored Ads (CMPS) | 2.7 | $32M | 850k | 38.15 | |
| Rapt Therapeutics (RAPT) | 2.7 | $32M | 1.0M | 31.79 | |
| Nkarta (NKTX) | 2.7 | $32M | 1.0M | 31.69 | |
| Turning Point Therapeutics I | 2.6 | $31M | 400k | 78.02 | |
| Kinnate Biopharma (KNTE) | 2.6 | $31M | 1.3M | 23.28 | |
| Forma Therapeutics Hldgs SHS | 2.5 | $30M | 1.2M | 24.89 | |
| Iovance Biotherapeutics (IOVA) | 2.5 | $29M | 1.1M | 26.02 | |
| Century Therapeutics (IPSC) | 2.4 | $29M | 989k | 29.34 | |
| Cytokinetics Com New (CYTK) | 2.3 | $28M | 1.4M | 19.79 | |
| Edgewise Therapeutics (EWTX) | 2.2 | $26M | 1.2M | 21.33 | |
| Apellis Pharmaceuticals (APLS) | 1.9 | $22M | 350k | 63.20 | |
| Bicycle Therapeutics Sponsored Ads (BCYC) | 1.8 | $22M | 715k | 30.36 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.8 | $21M | 940k | 22.21 | |
| Biomea Fusion (BMEA) | 1.5 | $18M | 1.2M | 15.61 | |
| Iveric Bio | 1.3 | $16M | 2.5M | 6.31 | |
| Gh Research Ordinary Shares (GHRS) | 1.3 | $16M | 724k | 21.73 | |
| Athira Pharma (ATHA) | 1.2 | $14M | 1.4M | 10.24 | |
| Janux Therapeutics (JANX) | 1.1 | $14M | 547k | 24.95 | |
| Kezar Life Sciences (KZR) | 1.0 | $13M | 2.3M | 5.43 | |
| Rain Therapeutics | 1.0 | $12M | 780k | 15.54 | |
| Aclaris Therapeutics (ACRS) | 1.0 | $12M | 675k | 17.56 | |
| Cogent Biosciences (COGT) | 1.0 | $12M | 1.4M | 8.11 | |
| Prelude Therapeutics (PRLD) | 1.0 | $12M | 400k | 28.63 | |
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 0.9 | $11M | 800k | 13.93 | |
| Harpoon Therapeutics | 0.9 | $11M | 800k | 13.87 | |
| Eledon Pharmaceuticals (ELDN) | 0.9 | $11M | 1.3M | 7.91 | |
| Landos Biopharma | 0.9 | $10M | 899k | 11.55 | |
| Repare Therapeutics Ord (RPTX) | 0.9 | $10M | 330k | 31.18 | |
| Talaris Therapeutics | 0.6 | $7.5M | 508k | 14.69 | |
| Cullinan Oncology (CGEM) | 0.6 | $7.4M | 289k | 25.75 | |
| Pmv Pharmaceuticals (PMVP) | 0.6 | $7.1M | 207k | 34.16 | |
| Monte Rosa Therapeutics (GLUE) | 0.6 | $6.8M | 300k | 22.70 | |
| Catabasis Pharmaceuticals In Com New | 0.6 | $6.7M | 3.2M | 2.11 | |
| Aslan Pharmaceuticals Ads | 0.6 | $6.6M | 2.0M | 3.30 | |
| Aligos Therapeutics (ALGS) | 0.4 | $4.3M | 213k | 20.39 | |
| C4 Therapeutics Com Stk (CCCC) | 0.4 | $4.3M | 113k | 37.84 | |
| Ikena Oncology (IKNA) | 0.4 | $4.2M | 300k | 14.04 | |
| Annexon (ANNX) | 0.3 | $3.6M | 160k | 22.51 | |
| Bctg Acquisition Corp | 0.2 | $2.3M | 200k | 11.38 | |
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.2 | $2.1M | 200k | 10.72 | |
| Passage Bio (PASG) | 0.1 | $1.7M | 125k | 13.24 | |
| Fs Development Corp Ii Com Cl A | 0.1 | $1.2M | 124k | 9.98 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.1 | $1.0M | 100k | 10.20 | |
| Research Alliance Corp Ii Com Cl A | 0.1 | $1.0M | 100k | 10.14 | |
| Day One Biopharmaceuticals I (DAWN) | 0.1 | $844k | 37k | 22.77 | |
| Helix Acquisition Corp Com Cl A | 0.0 | $518k | 50k | 10.36 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $173k | 67k | 2.60 | |
| Mereo Biopharma Group Ads (MREO) | 0.0 | $149k | 47k | 3.17 |
